+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ependymoma Drug"

Ependymoma - Pipeline Insight, 2024 - Product Thumbnail Image

Ependymoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
Ependymoma - Epidemiology Forecast - 2032 - Product Thumbnail Image

Ependymoma - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Ependymoma - Pipeline Review, H2 2019 - Product Thumbnail Image

Ependymoma - Pipeline Review, H2 2019

  • Drug Pipelines
  • November 2019
  • 237 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Ependymoma is a type of cancer that affects the central nervous system. It is a rare form of cancer, but it is the third most common type of brain tumor in children. Treatment for ependymoma typically involves surgery, radiation therapy, and chemotherapy. Drugs used to treat ependymoma are typically part of the larger Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological conditions, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. The CNS drug market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the CNS drug market include Pfizer, Novartis, Merck, GlaxoSmithKline, and Johnson & Johnson. Other companies, such as AbbVie, Bristol-Myers Squibb, and Eli Lilly, also have a presence in the CNS drug market. Show Less Read more